摘要目的：观察瑞舒伐他汀对ST段抬高型心肌梗死（STEMI）患者PCI术后血脂、心功能的影响。方法选取2012年5月至2014年4月贵阳医学院附属医院收治的急诊ST段抬高型心肌梗死（STEMI）且行急诊经皮冠状动脉介入（PCI）术成功的患者98例，将其随机分为对照组和观察组，各49例。对照组口服阿托伐他汀（20 mg），观察组口服瑞舒伐他汀（10 mg），6个月为一疗程。比较两组血脂、心功能指标，记录不良反应和主要不良心血管事件（MACE）。结果两组共95例患者（对照组47例，观察组48例）完成治疗。治疗6个月后，两组血脂指标血清总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）均显著改善，氨基末端脑利钠肽前体（NT-proBNP）显著降低，左室射血分数（LVEF）和心排指数（CI）显著增高（P<0.05）。与对照组相比，观察组TC、LDL和NT-proBNP均显著降低（P<0.05），其余指标相近。对照组不良反应发生率为19.1%（9/47），观察组为14.6%（7/48）；对照组MACE发生率为10.6%（5/47），观察组为8.3%（4/48）。两组不良反应发生率与MACE发生率差异均无统计学意义（均P>0.05）结论与阿托伐他汀相比，瑞舒伐他汀具有更好的改善STEMI并行PCI术患者的血脂水平和心功能的作用。

abstractsObjective To observe the clinical effects of rosuvastatin on blood lipid and heart function in patients with ST-elevation myocardial infarction (STEMI) after PCI. Methods From May 2012 to April 2014,98 patients with STEMI after PCI were randomly divided into control group (49 cases) and study group (49 cases) in the Affiliated Hospital of Guiyang Medical College. The control group received atorvastatin (20 mg), the study group received rosuvastatin (10 mg). All treated for 6 months. The blood lipid and heart function were compared, the adverse reactions and major adverse cardiac events (MACE) were recorded. Results A total of 95 patients completed treatment in the two groups (47 cases in control group, 48 cases in study group). After treatment of 6 months, the blood lipid (TC, TG, LDL and HDL) improved, the level of N-terminal pro-brain natriuretic peptide (NT-proBNP) decreased, left ventricular ejection fraction (LVEF) and cardiac index (CI) increased in the two groups (P<0.05). Compared with control group, the level of TC, LDL and NT-proBNP decreased greatly in the study group (P<0.05);the other indexes were similar between two groups. The control group adverse reaction rate was 19.1%(9/47), the observation group was 14.6%(7/48);the control group, the incidence rate of MACE was 10.6%(5/47), the observation group was 8.3%(4/48). The adverse effects and MACE of the two groups were no statistically significant difference. Conclusions Compared with atorvastatin, rosuvastatin showed better effects in improving blood lipid and heart function in patients with STEMI after PCI.